Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
An Economist editorial examines the relief and recovery efforts in Haiti and the "vital" importance of planning for rebuilding the country "before the world's generosity turns to cynicism. Fortunately there is a blueprint, drawn up by Haiti's government and presented to donors last year. It calls for investment to be targeted on infrastructure, basic services and combating soil erosion to make farmers more productive and the country less vulnerable to hurricanes. The pressing question is who should do it and how."
BioSyent Inc. ("BioSyent") announces that its subsidiary BioSyent Pharma Inc. has signed a license and distribution agreement with Notlers for VirsaniTM personal sanitizer.
BioTech Medics, Inc. announced today that they have begun the pre-production stage of creating two minute, sixty second and thirty second direct response TV and radio commercials for nationwide distribution for its proprietary SHBAN™ Alcohol Free Antiseptic Hand Sanitizer.
A new study published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091884 concerning the severity of H1N1 influenza has found that admissions to an intensive care unit (ICU) were associated with a longer interval between symptom onset and treatment with antivirals and with presence of an underlying medical condition.
Seasonal flu activity typically peaks in January or later, according to the Centers for Disease Control and Prevention (CDC), and the flu virus can spread as late as May. On top of the rising seasonal flu activity, this season the 2009 H1N1 virus is also circulating. Organizations – and particularly mass transportation systems where many people pass through daily – need to be ready to combat and help prevent the further spread of both flu viruses this winter and spring.
The BC Centre for Disease Control has launched an influenza genome sequencing project to better understand how the pandemic H1N1 flu virus has evolved in British Columbia, and may continue to evolve in the coming months.
Ordinary face masks and hand hygiene can effectively reduce the transmission of influenza-like illness during flu season. The finding comes from a new study, now available online (http://www.journals.uchicago.edu/doi/abs/10.1086/650396), published in the Feb. 15 issue of the Journal of Infectious Diseases.
Net sales for the first quarter of fiscal 2010 were $42,457,000 as compared to $34,293,000 for the same period of the prior fiscal year, an increase of 24%. Net earnings for the first quarter of fiscal 2010 were $8,921,000 or $0.22 per diluted share, both increases of 10% over the first quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,185,000 and 41,125,000, respectively.
UnitedHealth Group today reported growth in revenues and net earnings per share in 2009. The Company earned $0.81 per share in the fourth quarter, bringing full year 2009 net earnings to $3.24 per share.
Throughout the month of September, East Texas Medical Center Athens (ETMC Athens) has seen a 42% average increase in number of patients per day and is taking it in stride. Improved efficiencies in the Emergency Department facilitated by a process improvement firm, Compirion Healthcare, have allowed the hospital to absorb the volume and see an improvement in quality.
Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.
Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering.
Covidien plc today reported results for the first quarter of fiscal 2010 (October – December 2009). First-quarter net sales of $2.7 billion were up 7% from the $2.6 billion reported a year ago, with favorable foreign exchange of $121 million increasing the quarterly sales growth rate by approximately 5 percentage points.
Combining technology and animal health, a group of Kansas State University researchers is developing a more effective way to predict the spread of foot-and-mouth disease and the impact of preventative measures.
Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.
Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.
FDA Commissioner Margaret A. Hamburg today sent a letter to America's health care professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on safety monitoring of the 2009 H1N1 vaccines.
Journal of the American Medical Association: Funding of US Biomedical Research, 2003-2008 - After doubling in a decade, the rate of increase in biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjusting for inflation, the authors of this study report.
The rapid and widespread entry of the pandemic H1N1 infection that led to a large number of infected cases in Australia suggested a public health management failure in containing the pandemic when it broke out in April 2009.
Scientists have developed an alternative method for producing the active ingredient in Tamiflu-, the mainstay for fighting H1N1 and other forms of influenza. The new process could expand availability of the drug by reducing its cost, which now retails for as about $8 per dose.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.